Medical treatment of hypercortisonism was first used only in patients with adrenal carcinomas. In the past few years a variety of medical treatments have become available for Cushing’s disease as well. Some drugs act directly at the adrenal level: (1) OP’DDD should be started in inpatients at a high dosage (10–12 g/day) for 15–30 days; thereafter, a lower dose (8–10 g/day) is administered to outpatients for about 6 months under steroid replacement with hydrocortisone (30 mg/day) and 9 α-fluorohydrocortisone (50 µg/day). (2) Aminoglutethimide acts more rapidly at a dose of 1–2 g/day. An escape phenomenon may be observed due to ACTH hypersecretion overriding the pharmacological block. (3) Metyrapone has been used successfully in association with pituitary irradiation. Recently, WIN 24540 (Trilostane®), a 3-β-ol-dehydrogenase inhibitor has been tried but escape phenomena have also occurred. Among drugs acting at the hypothalamo-pituitary level, cyproheptadine and bromocriptine have been reported by some authors (but not all) to be efficient in the treatment of Cushing’s disease. Medical treatment at the adrenal level can now replace the bilateral adrenalectomy which used to be done previously. This should be considered only after having ruled out any possibility of adrenal tumor. OP’DDD is the drug of choice and its efficiency can be judged after 6 months of treatment. In our experience, almost 60% of patients with Cushing’s disease have been controlled after one or several courses of OP’DDD. The medical treatment can be combined with pituitary irradiation. When OP’DDD proves to be inefficient, surgery should not be delayed and will often reveal adrenal microadenomas. Medical treatment of hypercortisonism is also used to prepare patients for surgery in order to prevent postsurgical complications. Drugs are useful in hypercortisonism due to malignancies: we use OP’DDD (at a mean dosage of 12 g/day) in adrenal carcinomas in case of incomplete removal, metastases, and also to prevent possible recurrences. In many cases, tumor regressions have been observed and the mean survival is now 30 months as compared to 8.4 months before OP’DDD was given. In case of ectopic ACTH syndrome, tumor removal is rarely possible; in these situations medical treatment is also most beneficial.